Clinical outcomes among persons with pulmonary tuberculosis caused by Mycobacterium tuberculosis isolates with phenotypic heterogeneity in results of drug-susceptibility tests

Journal of Infectious Diseases

Volumn 209, Issue 11, 2014, Pages 1754-1763

  Zetola, Nicola M ^a,c,d,e   Modongo, Chawangwa ^c,e   Moonan, Patrick K ^b   Ncube, Ronald ^f   Matlhagela, Keikantse ^d   Sepako, Enoch ^d   Collman, Ronald G ^a   Bisson, Gregory P ^a,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c BOTSWANA UPENN PARTNERSHIP   (Botswana)

^d UNIVERSITY OF BOTSWANA   (Botswana)

^e PRINCESS MARINA HOSPITAL   (Botswana)

^f Ministry of Health   (Botswana)

Author keywords

drug susceptibility testing; mixed infection, heteroresistance; multidrug resistant tuberculosis; treatment outcome; Tuberculosis

Indexed keywords

ISONIAZID; RIFAMPICIN;

ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG TREATMENT FAILURE; FEMALE; GENETIC HETEROGENEITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; OUTCOME ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL; TREATMENT RESPONSE; YOUNG ADULT;

DRUG SUSCEPTIBILITY TESTING; MIXED INFECTION, HETERORESISTANCE; MULTIDRUG-RESISTANT TUBERCULOSIS; TREATMENT OUTCOME; TUBERCULOSIS;

ADULT; ANTITUBERCULAR AGENTS; BOTSWANA; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MALE; MYCOBACTERIUM TUBERCULOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 84900565509     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu040     Document Type: Article

References (35)

1. Cohen T, van Helden PD,Wilson D, et al. Mixed-strain mycobacterium tuberculosis infections and the implications for tuberculosis treatment and control. Clin Microbiol Rev 2012; 25: 708-19.
2. Hingley-Wilson SM, Casey R, Connell D, et al. Undetected multidrugresistant tuberculosis amplified by first-line therapy in mixed infection. Emerg Infect Dis 2013; 19: 1138-41.
3. Van Deun A, Aung KJ, Bola V, et al. Rifampin drug resistance tests for tuberculosis: challenging the gold standard. J Clin Microbiol 2013; 51: 2633-40.
4. Garcia de Viedma D, Marin M, Ruiz Serrano MJ, Alcala L, Bouza E. Polyclonal and compartmentalized infection by Mycobacterium tuberculosis in patients with both respiratory and extrarespiratory involvement. J Infect Dis 2003; 187: 695-9.
5. Glynn JR, Yates MD, Crampin AC, et al. DNA fingerprint changes in tuberculosis: reinfection, evolution, or laboratory error? J Infect Dis 2004; 190: 1158-66.
6. Martin A, Herranz M, Ruiz Serrano MJ, Bouza E, Garcia de Viedma D. The clonal composition of Mycobacterium tuberculosis in clinical specimens could be modified by culture. Tuberculosis 2010; 90: 201-7.
7. van Rie A, Victor TC, Richardson M, et al. Reinfection and mixed infection cause changing Mycobacterium tuberculosis drug-resistance patterns. Am J Respir Crit Care Med 2005; 172: 636-42.
8. Somoskovi A, Deggim V, Ciardo D, Bloemberg GV. Diagnostic implications of inconsistent results obtained with the Xpert MTB/Rif assay in detection of Mycobacterium tuberculosis isolates with an rpoB mutation associated with low-level rifampin resistance. J Clin Microbiol 2013; 51: 3127-9.
9. Caminero JA, de March P. Statements of ATS, CDC, and IDSA on treatment of tuberculosis. AmJ Respir Crit CareMed 2004; 169: 316-7; author reply 7.
10. Caminero JA, Sotgiu G, Zumla A, Migliori GB. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis 2010; 10: 621-9.
11. Falzon D, Jaramillo E, Schunemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011; 38: 516-28.
12. Botswana National Tuberculosis Programme report. Botswana Ministry of Health, Gaborone, Botswana, 2009.
13. Jindani A, Dore CJ, Mitchison DA. Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days. Am J Respir Crit Care Med 2003; 167: 1348-54.
14. Velayati AA, Farnia P, Mozafari M, et al. High prevelance of rifampinmonoresistant tuberculosis: a retrospective analysis among Iranian pulmonary tuberculosis patients. Am J Trop Med Hyg 2013.
15. Zetola NM, Modongo C, Kip EC, Gross R, Bisson GP, Collman RG. Alcohol use and abuse among patients with multidrug-resistant tuberculosis in Botswana. Int J Tuberc Lung Dis 2012; 16: 1529-34.
16. Modongo C, Zetola NM. Prevalence of hypothyroidism among MDRTB patients in Botswana. Int J Tuberc Lung Dis 2012; 16: 1561-2.
17. Ministry of Health of Botswana. BIAS 3 Report. 2008.
18. Cruciani M, Scarparo C, Malena M, Bosco O, Serpelloni G, Mengoli C. Meta-analysis of BACTEC MGIT 960 and BACTEC 460 TB, with or without solid media, for detection of mycobacteria. J Clin Microbiol 2004; 42: 2321-5.
19. Madison B, Robinson-Dunn B, George I, et al. Multicenter evaluation of ethambutol susceptibility testing of mycobacterium tuberculosis by agar proportion and radiometric methods. J Clin Microbiol 2002; 40: 3976-9.
20. van Rie A, Warren R, Richardson M, et al. Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment. N Engl J Med 1999; 341: 1174-9.
21. Cohen T, Wilson D, Wallengren K, Samuel EY, Murray M. Mixedstrain Mycobacterium tuberculosis infections among patients dying in a hospital in KwaZulu-Natal, South Africa. J Clin Microbiol 2011; 49: 385-8.
22. Borgdorff MW, van Soolingen D. The re-emergence of tuberculosis: what have we learnt from molecular epidemiology? Am J Trop Med Hyg 2014; 90: 99-105.
23. Becerra MC, Appleton SC, Franke MF, et al. Tuberculosis burden in households of patients with multidrug-resistant and extensively drugresistant tuberculosis: a retrospective cohort study. Lancet 2011; 377: 147-52.
24. Caminero JA, Pena MJ, Campos-Herrero MI, et al. Exogenous reinfection with tuberculosis on a European island with a moderate incidence of disease. Am J Respir Crit Care Med 2001; 163: 717-20.
25. Cohen T, Colijn C, Finklea B, Murray M. Exogenous re-infection and the dynamics of tuberculosis epidemics: local effects in a network model of transmission. J R Soc Interface 2007; 4: 523-31.
26. Cohen T, Murray M, Abubakar I, et al. Multiple introductions of multidrug- resistant tuberculosis into households, Lima, Peru. Emerg Infect Dis 2011; 17: 969-75.
27. Huyen MN, Kremer K, Lan NT, et al. Mixed tuberculosis infections in rural South Vietnam. J Clin Microbiol 2012; 50: 1586-92.
28. Gagneux S, Long CD, Small PM, Van T, Schoolnik GK, Bohannan BJ. The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science 2006; 312: 1944-6.
29. Gagneux S, Small PM. Global phylogeography of Mycobacterium tuberculosis and implications for tuberculosis product development. Lancet Infect Dis 2007; 7: 328-37.
30. Pillay M, Sturm AW. Evolution of the extensively drug-resistant F15/LAM4/KZN strain of Mycobacterium tuberculosis in KwaZulu-Natal, South Africa. Clin Infect Dis 2007; 45: 1409-14.
31. Al-Hajoj SA, Akkerman O, Parwati I, et al. Microevolution of Mycobacterium tuberculosis in a tuberculosis patient. J Clin Microbiol 2010; 48: 3813-6.
32. Navarro Y, Herranz M, Perez-Lago L, et al. Systematic survey of clonal complexity in tuberculosis at a populational level and detailed characterization of the isolates involved. J Clin Microbiol 2011; 49: 4131-7.
33. Perez-Lago L, Herranz M, Lirola MM, Bouza E, Garcia de Viedma D. Characterization of microevolution events in Mycobacterium tuberculosis strains involved in recent transmission clusters. J Clin Microbiol 2011; 49: 3771-6.
34. Sibanda T, Tedla Z, Nyirenda S, et al. Anti-tuberculosis treatment outcomes in HIV-infected adults exposed to isoniazid preventive therapy in Botswana. Int J Tuberc Lung Dis 2013; 17: 178-85.
35. Samandari T, Agizew TB, Nyirenda S, et al. 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial. Lancet 2011; 377: 1588-98.